Ceftriaxone Dosing for Acute Mastoiditis
For acute mastoiditis, use ceftriaxone 50 mg/kg IV/IM once daily in children (maximum 2 g) and 2 g IV once daily in adults, administered for 10 days.
Pediatric Dosing
The WHO Pocket Book of Hospital Care for Children specifically recommends 50-80 mg/kg IV daily as second-line therapy for mastoiditis 1. The FDA label supports 50-75 mg/kg/day for serious infections in children, with a maximum daily dose of 2 grams 2.
Key pediatric considerations:
- Neonates: Avoid in premature infants and those ≤28 days requiring calcium-containing IV solutions due to precipitation risk 2
- Infants: Administer IV doses over 60 minutes (not 30 minutes) to reduce bilirubin encephalopathy risk 2
- Standard dosing: 50 mg/kg once daily is adequate for most cases
- Higher dosing: Up to 75-80 mg/kg may be used for severe infections, but 50 mg/kg is typically sufficient
Adult Dosing
Adults should receive 2 g IV once daily, which is the standard dose for serious infections 2. This provides adequate coverage for common mastoiditis pathogens including Streptococcus pneumoniae, Streptococcus pyogenes, and Haemophilus influenzae 3, 4.
Treatment Duration and Route
Duration: 10 days is the recommended treatment course 1. Clinical studies demonstrate that most patients show improvement within 24 hours of initiating therapy 5.
Route of administration:
- IV administration is preferred for hospitalized patients
- IM administration is acceptable for outpatient management once clinical stability is achieved 6, 5
- Outpatient therapy with once-daily IM ceftriaxone has shown 96.8% cure rates in children with mastoiditis with periosteitis 6
Clinical Management Algorithm
Initial assessment:
- Confirm diagnosis with clinical findings: postauricular erythema, mastoid tenderness, pinna displacement, fever 4
- Obtain CT temporal bones with IV contrast if diagnosis uncertain or complications suspected 4
- Perform myringotomy for drainage 6
Treatment pathway:
- Start ceftriaxone at above doses immediately
- Hospitalize initially if: severe systemic symptoms, intracranial complications, subperiosteal abscess, or bony erosion present 7
- Consider outpatient management after 24-48 hours if: clinical improvement, no complications, reliable follow-up available 6, 5
- Daily evaluation by otolaryngology and infectious disease specialists is essential for outpatient cases 6
Important Caveats
First-line therapy: Cloxacillin/flucloxacillin 50 mg/kg QDS is actually the WHO's first-line recommendation, with ceftriaxone as second-line 1. However, ceftriaxone is widely used as first-line in many settings due to once-daily dosing convenience and broader coverage.
Pathogen coverage: Ceftriaxone provides excellent coverage for S. pneumoniae, S. pyogenes, and H. influenzae - the most common mastoiditis pathogens 5, 3, 4. However, it has no activity against Pseudomonas aeruginosa 5, which may require alternative therapy if suspected.
Surgical intervention: Medical management alone is appropriate for uncomplicated mastoiditis (no bony erosion, no SPA, no intracranial complications) 7. Mastoidectomy is reserved for complicated cases or treatment failures 6, 7.
Renal function: No dose adjustment needed for renal or hepatic impairment in standard dosing 2, though patients with augmented renal clearance (eGFR >120 mL/min/1.73m²) may have suboptimal drug levels for organisms with MIC ≥4 mg/L 8.